NASDAQ: CRME TSX: COM
Company Will Also Host Xydalba Expert
Educational Session Featuring Key Opinion Leaders in the
Field of Hospital Anti-Infectives
VANCOUVER, April 12, 2018 /PRNewswire/ - Cardiome
Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating,
specialty pharmaceutical company focused on commercializing
hospital drugs, today announced 15 data presentations taking place
at the 28th European Congress of Clinical Microbiology
and Infectious Disease (ECCMID), being held April 21-24, 2018 in Madrid, Spain. The presentations will
include data for the Company's commercial anti-infective assets,
Xydalba™ (dalbavancin hydrochloride) and Zevtera/Mabelio
(ceftobiprole), an intravenous (IV) cephalosporin antibiotic with
rapid bactericidal activity against a wide range of Gram-positive
and Gram-negative bacteria, including methicillin-resistant
Staphylococcus aureus (MRSA) and Pseudomonas
aeruginosa.
In addition to the data presentations at the meeting, Cardiome
will also be hosting an educational session featuring presentations
by several physician experts regarding emerging anti-infective
treatments and clinical experience with Xydalba, the first and only
30-minute, one-dose treatment option for acute bacterial skin and
skin structure infections (ABSSSI). The details for the
Xydalba symposium are as follows:
- Session title: Paradigm Shift in the Treatment of
Gram-positive Infections
Chairpersons: Christian
Chidiac, Croix-Rousse Hospital, Lyon, and Luis Eduardo
Lopez-Cortes, University Hospital Virgen Macarena,
Sevilla
Speakers: David Livermore,
Norwich Medical School, Norwich,
Beatrice Grabein, University of
Munich Grosshadern, Klaus Freidrich
Bodmann, Werner Forßmann Hospital, Eberswalde, Aurelien Dinh, HU Raymond Poincare APHP,
Paris, Neil Ritchie, Queen Elizabeth University
Hospital Glasgow, Glasgow
Date and time: Saturday, 21 April
2018 from 16:30 – 18:30
CEST
Onsite location: Hall K
Cardiome currently markets Xydalba in France, Germany, the UK, the Republic of Ireland, Netherlands, Finland and Sweden. The Company
currently markets ceftobiprole under the brand name Mabelio in
Italy and France and under the brand name Zevtera in the
UK, Germany, Austria and Switzerland, and will soon be launching
Zevtera in Spain.
The details for the data presentations at ECCMID are as
follows:
Xydalba presentations
Title: Reduced hospital stays for skin infections treated
with dalbavancin
Lead author: Robert Laing,
Aberdeen, United
Kingdom
Date and time: Saturday, 21 April 2018; 15:30 – 16:30 CEST
Location: Paper Poster Arena
Poster number: #P0282
Session info: PS018 – Clinical trial experience – new
antibacterial agents
Title: Simulated dalbavancin exposures select for
dalbavancin-nonsusceptible, vancomycin-intermediate (VISA) strains
of methicillin-resistant Staphylococcus aureus (MRSA) in in vitro
pharmacokinetic/pharmacodynamic models
Lead author: Brian Werth,
Seattle, WA, USA
Date and time: Saturday, 21 April
2018; 15:30 – 16:30 CEST
Location: Paper Poster Arena
Poster number: #P0264
Session info: PS017 – Preclinical PK/PD
Title: Long-term outcomes of dalbavancin for the
treatment of osteomyelitis in adult patients
Date and time: Monday, 23 April
2018; 09:00 – 10:00 CEST
Lead author: Urania Rappo, Jersey City, NJ, USA
Location:
ePoster Arena 3
ePoster number: #O0697 (mini oral session)
Session info: OE133 – Osteomyelitis: Optimal treatment
options
Title: Can dalbavancin be used as a catheter lock
solution?
Date and time: Monday, 23 April
2018; 12:30 – 13:30 CEST
Lead author: María Guembe, Madrid, Spain
Location: Paper
Poster Arena
Poster number: #P1425
Session info: PS072 – Biofilms I – Gram-positive
pathogens
Title: Dalbavancin as treatment for endocarditis and/or
bloodstream infections produced by Gram-positive
cocci
Lead author: Carmen Hidalgo
Tenorio, Granada,
Spain
Date and time:
Tuesday, 24 April 2018; 12:30 –
13:30 CEST
Location: Paper Poster Arena
Poster number: #P2017
Session info: PS099 – What is new in infective
endocarditis?
Title: In vitro activity of dalbavancin against
daptomycin-unsusceptible and daptomycin-high-level-resistant MRSA
and MSSA
Lead author: Juan-Luis
Munoz-Bellido, Salamanca, Spain
Date and time: Tuesday,
24 April 2018; 12:30 – 13:30
CEST
Location: Paper Poster Arena
Poster number: #P2060
Session info: PS102 – MRSA: epidemiology and
susceptibility
Title: In vitro antibacterial and bactericidal activity
of dalbavancin against different multidrug resistant (MDR)
Staphylococcus aureus strains
Lead author: Floriana
Campanile, Catania, Italy
Date and time: Tuesday,
24 April 2018; 12:30 – 13:30 CEST
Location: Paper Poster Arena
Poster number: #P2061
Session info: PS102 – MRSA: epidemiology and
susceptibility
Title: In vitro activity of tedizolid, dalbavancin and
ceftobiprole against Clostridium difficile
Date and time: Monday, 23 April
2018; 13:30 – 14:30 CEST
Lead author: Avi Peretz,
Teberias, Israel
Location: Paper Poster
Arena
Poster number: #P1844
Session info: PS091 – Resistance in various
Gram-positives
Zevtera Presentations
Title: Activity of ceftobiprole and comparators against a
collection of teicoplanin- and/or linezolid-resistant
coagulase-negative staphylococci from bloodstream
infections
Lead author: Marco Coppi,
Florence, Italy
Date
and time: Saturday, 21 April to Tuesday, 24 April 2018
Location: ePoster terminals
ePoster number: #E0003
Session info: EV001 – MRSA: Antibacterial susceptibility and
resistance
Title: Activity of ceftobiprole and comparators against
European respiratory-tract isolates of MSSA and MRSA from
2016
Lead author: Ian Morrissey,
Monthey, Switzerland
Date and time:
Saturday, 21 April to Tuesday, 24 April
2018
Location: ePoster terminals
ePoster number: #E0006
Session info: EV001 – MRSA: Antibacterial susceptibility and
resistance
Title: Ceftobiprole versus vancomycin in treatment of
methicillin-resistant Staphylococcus aureus (MRSA) meningitis in an
experimental rabbit model
Lead author: Oguz, Resat
Sipahi, Izmir, Turkey
Date and time: Saturday,
21 April 2018; 15:30 – 16:30 CEST
Location: Paper Poster Arena
Poster number: #P0263
Session info: PS017 – Preclinical PK/PD
Title: In vitro susceptibility testing of cerufoxime,
cefixime, cefpodoxime, cefotaxime, ceftaroline, ceftobiprole,
linezolid and tedizolid against isolates of Nocardia by using the
E-test method
Lead author: Veronica
Rodriguez-Nava, Lyon,
France
Date and time: Monday, 23 April 2018; 13:30 – 14:30 CEST
Location: Paper Poster Arena
Poster number: #P1841
Session info: PS091 – Resistance in various
Gram-positives
Title: In vivo assessment of ceftobiprole versus
daptomycin in a murine model of Staphylococcus aureus bacteremia:
antimicrobial activity and impact on host inflammatory
response
Lead author: Cédric Jaqueline, Nantes, France
Date and time: Tuesday,
24 April 2018; 12:30 – 13:30 CEST
Location: Paper Poster Arena
Poster number: #P2025
Session info: PS100 – News on staphylococcal bloodstream
infection
Title: Epidemiology and ceftobiprole susceptibility of
European Enterobacteriaceae and Gram-positive clinical isolates
from different infection sources collected in 2016
Lead author: Stephen Hawser, Monthey, Switzerland
Date and time:
Tuesday, 24 April 2018; 12:30 –
13:30 CEST
Location: Paper Poster Arena
Poster number: #P2441
Session info: PS122 – Other (new) beta-lactams: In vitro
activity against Gram-negatives
Title: Bactericidal and synergistic activity of
ceftobiprole combined with different antibiotics against selected
Gram-positive isolates
Lead author: Floriana
Campanile, Catania, Italy
Date and time: Tuesday,
24 April 2018; 12:30 – 13:30 CEST
Location: Paper Poster Arena
Poster number: #P2498
Session info: PS125 – Various aspects of antimicrobial
susceptibility testing
About Xydalba™ (dalbavancin hydrochloride)
Xydalba™ (dalbavancin hydrochloride) for infusion is a second
generation, semi-synthetic lipoglycopeptide, which consists of a
lipophilic side-chain added to an enhanced glycopeptide backbone.
Xydalba is the first and only 30-minute, one-dose treatment option
for acute bacterial skin and skin structure infections (ABSSSI)
that delivers a full course of IV therapy. Xydalba can be
administered as either one 1500 mg dose or as a two-dose regimen of
1000 mg followed one week later by 500 mg, each administered over
30 minutes. Xydalba demonstrates bactericidal activity in vitro
against a range of Gram-positive bacteria, such as Staphylococcus
aureus (including methicillin-resistant, also known as MRSA,
strains) and Streptococcus pyogenes, as well as certain other
streptococcal species. Dalbavancin was approved by the U.S.
Food and Drug Administration in 2014 for the treatment of adult
patients with ABSSSI caused by susceptible Gram-positive bacteria,
including methicillin resistant staphylococcus aureus (MRSA) and is
commercialized under the trade name DALVANCE®.
Dalbavancin was also approved by the European Medicines Agency for
the treatment of ABSSSIs in adults and is commercialized under the
tradename Xydalba. Xydalba is marketed by Cardiome in six
countries, including the United
Kingdom, France,
Germany, Sweden, Finland and the Republic of Ireland.
About Zevtera® / Mabelio®
(ceftobiprole)
Zevtera® (ceftobiprole medocaril sodium) is a
cephalosporin antibiotic for intravenous administration with rapid
bactericidal activity against a wide range of Gram-positive and
Gram-negative bacteria, including methicillin-susceptible and
resistant Staphylococcus aureus (MSSA, MRSA) and susceptible
Pseudomonas spp. Ceftobiprole is currently approved for sale
in 13 European countries and several non-European countries for the
treatment of adult patients with community-acquired pneumonia (CAP)
and hospital-acquired pneumonia (HAP), excluding
ventilator-associated pneumonia (VAP). Ceftobiprole is currently
commercialized in Italy,
France, Germany, the U.K., Austria and Switzerland under the brand name Zevtera or
Mabelio®.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a revenue-generating, specialty
pharmaceutical company focused on providing innovative,
high-quality brands that meet the needs of acute care physicians
and patients. With a commercial presence and distribution
network covering over 60 countries worldwide, Cardiome develops,
acquires and commercializes brands for the in-hospital, acute care
market segment. The Company's portfolio of approved and marketed
brands includes: Xydalba™ (dalbavancin hydrochloride),
for the treatment of acute bacterial skin and skin structure
infections (ABSSSI); Zevtera®/Mabelio®
(ceftobiprole medocaril sodium), a cephalosporin antibiotic for the
treatment of community- and hospital-acquired pneumonia (CAP, HAP);
Brinavess® (vernakalant IV) for the rapid conversion of
recent onset atrial fibrillation to sinus rhythm;
Aggrastat® (tirofiban hydrochloride) for the reduction
of thrombotic cardiovascular events in patients with acute coronary
syndrome, and Esmocard® and Esmocard Lyo®
(esmolol hydrochloride), a short-acting beta-blocker used to
control rapid heart rate in a number of cardiovascular indications.
Cardiome's pipeline of product candidates includes
Trevyent®, a drug device combination that is designed to
deliver Remodulin® (treprostinil) the world's leading treatment for
pulmonary arterial hypertension.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the
Toronto Stock Exchange (COM). For more information, please visit
our web site at www.cardiome.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 or forward-looking information under
applicable Canadian securities legislation ("forward-looking
statements") that may not be based on historical fact, including
without limitation statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. A discussion of the risks and uncertainties facing
Cardiome are discussed in our most recent annual and quarterly
reports and detailed from time to time in our other filings with
the Securities and Exchange Commission ("SEC") available at
www.sec.gov and the Canadian securities regulatory authorities at
www.sedar.com. All of the risks and certainties disclosed in
these filings are hereby incorporated by reference in their
entirety. While Cardiome makes these forward-looking statements in
good faith, given these risks, uncertainties and factors, you are
cautioned not to place undue reliance on any forward-looking
statements made in this press release. All forward-looking
statements made herein are based on our current expectations and we
undertake no obligation to revise or update such forward-looking
statements to reflect subsequent events or circumstances, except as
required by law.
Cardiome® and the Cardiome Logo are the proprietary
trademarks of Cardiome Pharma Corp.
Aggrastat® and Brinavess® are trademarks
owned by Cardiome and its affiliates worldwide.
Xydalba™ is a trademark of Durata Therapeutics Holding
C.V., and used under license.
Zevtera® and Mabelio® are trademarks owned by
Basilea Pharmaceutica International Ltd., and used under
license.
Esmocard® and Esmocard Lyo® are trademarks
owned by Orpha-Devel Handels und Vertriebs GmbH, and used under
license.
Trevyent® is a trademark of SteadyMed and used under
license.
DALVANCE® is a trademark of Allergan Pharmaceuticals
International Limited.
All other trademarks are the property of their respective
owners.
View original
content:http://www.prnewswire.com/news-releases/cardiome-announces-fifteen-xydalba-and-zevtera-abstracts-at-eccmid-2018-300628714.html
SOURCE Cardiome Pharma Corp.